Longevity News
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
Five patients with end-stage kidney disease received genetically engineered pig kidneys through an expanded access program, with three maintaining kidney function for over eight months without dialysis and two subsequently transitioning to human donor kidneys. This represents the first documented cases of xenotransplantation functioning as genuine bridge therapy, extending dialysis-free survival while preserving access to human organ transplantation.
Venus Healthcare Homes is exporting its integrated care-village model to Malaysia and across ASEAN, where demographic aging is compressing into a single decade—a timeline that demands infrastructure built for population-wide health maintenance rather than crisis management. The model positions healthy aging as an economic asset only when care systems reach beyond affluent populations to keep ordinary older people well and community-connected.
Function Health has launched a secure connector allowing users to feed personalized lab results and clinical notes into mainstream AI chatbots—ChatGPT, Claude, and Perplexity—enabling AI to provide answers grounded in individual biomarkers rather than population averages. This addresses a critical gap: AI health guidance has been generic and contextless, while over 80% of Function's members show at least one biomarker outside optimal ranges that warrant investigation and intervention.
Scribe Therapeutics has initiated human trials of STX-1150, a gene therapy designed to silence PCSK9 and reduce LDL cholesterol. Preclinical data in primates demonstrated sustained LDL reductions exceeding 50% at therapeutic doses, with potential implications for cardiovascular risk reduction in patients with familial hypercholesterolemia or statin-resistant disease.
FibroBiologics received a U.S. patent for a topical wound therapy using 3D fibroblast spheroids and fibroblast-derived materials, with preclinical evidence showing accelerated healing in diabetic and non-diabetic wound models. This approach addresses chronic wounds—a significant driver of morbidity and cost—by leveraging the regenerative capacity of fibroblast-derived signaling molecules rather than the cells themselves.
Mito Health, a direct-to-consumer diagnostics platform, has administered over one million tests across seven preventive categories including genomic sequencing, microbiome analysis, advanced imaging, and liquid biopsy screening. The expansion reflects growing demand for accessible, transparent-pricing diagnostic services that operate outside traditional insurance infrastructure.
Tim Maupin's film explores the ethical and personal dimensions of rejuvenation technology arriving before universal access, examining what happens when life-extension therapies can save some but not others. The narrative anchors longevity science in the lived human experience of aging parents and the institutional barriers that determine who benefits from breakthrough interventions.
Veradermics has secured $820 million in funding to advance VDPHL01, an oral extended-release formulation of minoxidil designed to treat pattern hair loss in men and women. The company reports positive Phase 2 data in women and plans confirmatory Phase 3 readouts in men by late 2026, positioning itself to become the first FDA-approved oral, non-hormonal hair loss treatment.
United Therapeutics' nebulized treprostinil met its primary endpoint in phase 3 trials for idiopathic pulmonary fibrosis, demonstrating a 111.8 mL absolute improvement in forced vital capacity over 52 weeks alongside reduced acute exacerbation risk. If approved, it would represent the first inhaled antifibrotic therapy for IPF, a progressive disease with limited treatment options.
Adenine base editing delivered via AAV9 achieved partial correction of the LMNA mutation in HGPS mice, rescuing structural bone defects and normalizing gene expression when administered at two weeks of age. This demonstrates that in vivo base editing can address monogenic bone disorders and establishes timing-dependent efficacy for genetic correction strategies.
The Longevity Science Foundation has extended its Invested in Her campaign deadline to October 1, 2026, targeting $250,000 to fund early-stage research into ovarian aging and menopause—a critical gap in women's health science that receives less than 1% of NIH funding despite its systemic impact on cardiometabolic, neurological, and skeletal health across the lifespan.
THPharm is using AI to identify additional therapeutic applications for THP-001, a metabolic drug currently in Phase 3 trials, by analyzing how the compound affects gene expression and biological pathways. This reverse-engineering approach reduces development risk and cost by leveraging existing safety data rather than starting clinical validation from scratch.